BioSpace News Archive

Colossal Biosciences, the breakthrough genetic engineering and de-extinction company, is pleased to announce the formation of the Tasmania Thylacine Advisory Committee.

858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer.

AtriCure, Inc. today announced that the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

Pangea Laboratory has received Breakthrough Device Designation from the US Food and Drug Administration for its non-invasive Bladder CARE™ Assay, intended for the quantitative urine-based diagnosis of bladder cancer and upper tract urothelial carcinoma in patients presenting with hematuria and suspected of having either cancer.

Ascendis Pharma A/S (Nasdaq: ASND) today announced new analyses from the blinded and ongoing open-label extension (OLE) portions of ACcomplisH, the Company’s Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial of TransCon CNP in children ages 2-10 years with achondroplasia

Sudo Biosciences announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital, Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital.

Coya Therapeutics, Inc. announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately.

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024.

Ocelot Bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead candidate OCE-205 for the treatment of ascites due to all etiologies except cancer.

RedHill Biopharma Ltd. today announced that its two novel, oral host-directed investigational drugs, opaganib[1] and RHB-107 (upamostat)[2], demonstrated robust synergistic effect when combined individually with remdesivir (Veklury®)[3], significantly improving viral inhibition while maintaining cell viability, in a new U.S. Army-funded and conducted Ebola virus in vitro study.